Lyell Immunopharma, Inc. (LYEL) NASDAQ
14.89
-2.26(-13.18%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 526.12M |
| Enterprise Value | 507.86M |
| P/E Ratio | -1.32 |
| PEG Ratio | 0.02 |
| Price/Sales Ratio | 11,207.89 |
| Price/Book Ratio | 1.19 |
| Enterprise/Revenue | 9,553.6 |
| Enterprise/EBITDA | -1.63 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | -7,948.58 |
| Operating Margin | -6,189.1 |
Management Effectiveness
| Return On Assets | -0.7 |
| Return On Equity | -0.86 |
Income Statement
| Revenue | 36,000 |
| Revenue/Share | 0 |
| Gross Profit | -11.5M |
| EBITDA | -192.24M |
| Net Income | -274.45M |
| Diluted EPS | -16.06 |
Balance Sheet
| Total Cash | 254.02M |
| Total Cash/Share | 11.61 |
| Total Debt | 39.49M |
| Total Debt/Equity | 0.14 |
| Current Ratio | 7.23 |
| Book Value Per Share | 12.51 |
Price History
| 52-Week Change | 81.14 |
| 52-Week High | 45 |
| 52-Week Low | 7.78 |
| Moving Average 50 Days | 20.44 |
| Moving Average 200 Days | 20.63 |
Statistics
| Average Volume | 86,036 |
| Shares Outstanding | 23.33M |
| % Held by Institutions | 70.06 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
| Last Split Date | June 02, 2025 |
